Your browser doesn't support javascript.
loading
Retrospective analyzes of adverse events during biologic agents in children with juvenile idiopathic arthritis from a single center in Turkey.
Balci, Sibel; Demir, Ilksen; Serbes, Mahir; Dogruel, Dilek; Altintas, Derya Ufuk; Ekinci, Rabia Miray Kisla.
Afiliación
  • Balci S; Department of Pediatric Rheumatology, Cukurova University Faculty of Medicine, Adana, Turkey.
  • Demir I; Department of Pediatrics, Cukurova University Faculty of Medicine, Adana, Turkey.
  • Serbes M; Department of Pediatric Allergy and Immunology, Cukurova University Faculty of Medicine, Adana, Turkey.
  • Dogruel D; Department of Pediatric Allergy and Immunology, Cukurova University Faculty of Medicine, Adana, Turkey.
  • Altintas DU; Department of Pediatric Allergy and Immunology, Cukurova University Faculty of Medicine, Adana, Turkey.
  • Ekinci RMK; Department of Pediatric Rheumatology, Cukurova University Faculty of Medicine, Adana, Turkey.
Reumatologia ; 58(6): 367-374, 2020.
Article en En | MEDLINE | ID: mdl-33456079
ABSTRACT

OBJECTIVES:

Juvenile idiopathic arthritis is the most common rheumatic disease in childhood. Biologic agents have changed the course of juvenile idiopathic arthritis. However, there are concerns regarding the occurrence of serious adverse events in patients receiving biologic agents. The aim of this study was to evaluate adverse events in children with juvenile idiopathic arthritis receiving biologic agents. MATERIAL AND

METHODS:

This retrospective study includes juvenile idiopathic arthritis patients receiving biologic agents. Demographic features and adverse events during biologic agents were collected from medical files. Adverse events that either resulted in death, were life-threatening, required inpatient hospitalization, or resulted in persistent or significant disability/incapacity were considered as serious adverse events.

RESULTS:

In total, 162 juvenile idiopathic arthritis patients (55.6% female) receiving biologic agents were enrolled 101 (62.3%) patients treated with etanercept, 27 (16.7) with tocilizumab, 14 (8.6%) with adalimumab, 15 (9.2%) with anti-interleukin 1 agents (13 canakinumab, 2 anakinra), and 5 (3.1%) with infliximab. 75.9% of the patients received concomitantly disease-modifying anti-rheumatic drugs, and 20.4% received disease-modifying anti-rheumatic drugs plus corticosteroid. The mean age at initiation of the biologic agent was 10.5 ±4.3 years. The mean age at the study enrolment was 12.1 ±4.5 years. The mean follow-up duration was 19.7 ±2.1 months. The most frequent adverse event was upper respiratory tract infections (54.3%) followed by urinary tract infections (21%). Anaphylaxis occurred in 3 patients (1.9%) 2 with tocilizumab and one with infliximab. Macrophage activation syndrome occurred in 1 patient (0.6%) receiving tocilizumab. Lung tuberculosis developed in 2 patients (1.2%) receiving canakinumab. The frequency of serious adverse events in total was 6.7%.

CONCLUSIONS:

While the most frequent adverse events during biologic agents was upper respiratory tract infections, the frequency of serious adverse events was 6.7%; therefore, juvenile idiopathic arthritis patients receiving biologic agents should be carefully evaluated for these adverse events in clinical practice.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Reumatologia Año: 2020 Tipo del documento: Article País de afiliación: Turquía

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Observational_studies Idioma: En Revista: Reumatologia Año: 2020 Tipo del documento: Article País de afiliación: Turquía